Using tumor tissues from 230 mCRC patients treated with oxaliplatin combined with 5-FU chemotherapy, Baraniskin et al. reported that SMAD4 expression was decreased in 34% of mCRC samples, and these patients had a shorter PFS and OS compared with patients in which SMAD4 is stably expressed [167]. This evidence concerns the gene SMAD4 and neoplasm.